Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
NEPH vs FELE vs GWW vs CNMD
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Industrial - Distribution
Medical - Devices
NEPH vs FELE vs GWW vs CNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Industrial - Machinery | Industrial - Distribution | Medical - Devices |
| Market Cap | $38M | $4.39B | $58.39B | $1.13B |
| Revenue (TTM) | $19M | $2.18B | $18.38B | $1.37B |
| Net Income (TTM) | $776K | $150M | $1.78B | $55M |
| Gross Margin | 59.2% | 35.2% | 39.2% | 53.6% |
| Operating Margin | 3.5% | 12.6% | 14.2% | 11.3% |
| Forward P/E | 32.0x | 21.6x | 27.7x | 8.4x |
| Total Debt | $1M | $280M | $3.16B | $835M |
| Cash & Equiv. | $5M | $100M | $585M | $41M |
NEPH vs FELE vs GWW vs CNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Nephros, Inc. (NEPH) | 100 | 45.1 | -54.9% |
| Franklin Electric C… (FELE) | 100 | 195.9 | +95.9% |
| W.W. Grainger, Inc. (GWW) | 100 | 398.5 | +298.5% |
| CONMED Corporation (CNMD) | 100 | 50.1 | -49.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEPH vs FELE vs GWW vs CNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NEPH carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 32.7%, EPS growth -10.1%, 3Y rev CAGR 23.5%
- Lower volatility, beta 0.58, Low D/E 10.4%, current ratio 4.06x
- Beta 0.58, current ratio 4.06x
- 32.7% revenue growth vs GWW's 4.5%
FELE lags the leaders in this set but could rank higher in a more targeted comparison.
GWW is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 37 yrs, beta 0.87, yield 0.8%
- 462.8% 10Y total return vs FELE's 229.5%
- 9.7% margin vs CNMD's 4.0%
- 19.7% ROA vs CNMD's 2.4%, ROIC 32.1% vs 5.8%
CNMD is the clearest fit if your priority is valuation efficiency.
- PEG 0.23 vs FELE's 2.48
- Lower P/E (8.4x vs 27.7x), PEG 0.23 vs 1.24
- 2.2% yield, 2-year raise streak, vs GWW's 0.8%, (1 stock pays no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.7% revenue growth vs GWW's 4.5% | |
| Value | Lower P/E (8.4x vs 27.7x), PEG 0.23 vs 1.24 | |
| Quality / Margins | 9.7% margin vs CNMD's 4.0% | |
| Stability / Safety | Beta 0.58 vs CNMD's 1.32, lower leverage | |
| Dividends | 2.2% yield, 2-year raise streak, vs GWW's 0.8%, (1 stock pays no dividend) | |
| Momentum (1Y) | +76.9% vs CNMD's -35.7% | |
| Efficiency (ROA) | 19.7% ROA vs CNMD's 2.4%, ROIC 32.1% vs 5.8% |
NEPH vs FELE vs GWW vs CNMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NEPH vs FELE vs GWW vs CNMD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GWW leads in 2 of 6 categories
CNMD leads 1 • NEPH leads 0 • FELE leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GWW leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GWW is the larger business by revenue, generating $18.4B annually — 961.0x NEPH's $19M. GWW is the more profitable business, keeping 9.7% of every revenue dollar as net income compared to CNMD's 4.0%. On growth, GWW holds the edge at +10.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $19M | $2.2B | $18.4B | $1.4B |
| EBITDAEarnings before interest/tax | $806,000 | $322M | $2.9B | $219M |
| Net IncomeAfter-tax profit | $776,000 | $150M | $1.8B | $55M |
| Free Cash FlowCash after capex | -$348,000 | $169M | $1.4B | $124M |
| Gross MarginGross profit ÷ Revenue | +59.2% | +35.2% | +39.2% | +53.6% |
| Operating MarginEBIT ÷ Revenue | +3.5% | +12.6% | +14.2% | +11.3% |
| Net MarginNet income ÷ Revenue | +4.1% | +6.9% | +9.7% | +4.0% |
| FCF MarginFCF ÷ Revenue | -1.8% | +7.8% | +7.5% | +9.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.9% | +9.9% | +10.1% | -0.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -81.0% | +13.4% | +18.2% | +136.8% |
Valuation Metrics
CNMD leads this category, winning 7 of 7 comparable metrics.
Valuation Metrics
At 24.3x trailing earnings, CNMD trades at a 30% valuation discount to GWW's 34.9x P/E. Adjusting for growth (PEG ratio), CNMD offers better value at 0.67x vs FELE's 3.51x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $38M | $4.4B | $58.4B | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $34M | $4.6B | $61.0B | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | 32.00x | 30.57x | 34.85x | 24.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.64x | 27.70x | 8.41x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.51x | 1.56x | 0.67x |
| EV / EBITDAEnterprise value multiple | 26.34x | 13.74x | 20.70x | 9.96x |
| Price / SalesMarket cap ÷ Revenue | 2.03x | 2.06x | 3.25x | 0.82x |
| Price / BookPrice ÷ Book value/share | 3.78x | 3.39x | 14.30x | 1.11x |
| Price / FCFMarket cap ÷ FCF | 23.23x | 22.67x | 43.87x | 7.51x |
Profitability & Efficiency
GWW leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
GWW delivers a 43.1% return on equity — every $100 of shareholder capital generates $43 in annual profit, vs $5 for CNMD. NEPH carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNMD's 0.81x. On the Piotroski fundamental quality scale (0–9), GWW scores 8/9 vs CNMD's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.7% | +11.4% | +43.1% | +5.4% |
| ROA (TTM)Return on assets | +5.9% | +7.6% | +19.7% | +2.4% |
| ROICReturn on invested capital | +14.2% | +14.7% | +32.1% | +5.8% |
| ROCEReturn on capital employed | +11.2% | +18.1% | +39.7% | +7.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.10x | 0.21x | 0.76x | 0.81x |
| Net DebtTotal debt minus cash | -$4M | $181M | $2.6B | $794M |
| Cash & Equiv.Liquid assets | $5M | $100M | $585M | $41M |
| Total DebtShort + long-term debt | $1M | $280M | $3.2B | $835M |
| Interest CoverageEBIT ÷ Interest expense | 588.00x | 24.75x | 32.42x | 5.20x |
Total Returns (Dividends Reinvested)
Evenly matched — NEPH and GWW each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GWW five years ago would be worth $26,784 today (with dividends reinvested), compared to $2,818 for CNMD. Over the past 12 months, NEPH leads with a +76.9% total return vs CNMD's -35.7%. The 3-year compound annual growth rate (CAGR) favors NEPH at 33.2% vs CNMD's -31.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -25.9% | +3.0% | +23.1% | -9.3% |
| 1-Year ReturnPast 12 months | +76.9% | +14.9% | +18.8% | -35.7% |
| 3-Year ReturnCumulative with dividends | +136.2% | +9.4% | +85.3% | -68.4% |
| 5-Year ReturnCumulative with dividends | -54.4% | +21.6% | +167.8% | -71.8% |
| 10-Year ReturnCumulative with dividends | +11.7% | +229.5% | +462.8% | +3.5% |
| CAGR (3Y)Annualised 3-year return | +33.2% | +3.0% | +22.8% | -31.9% |
Risk & Volatility
Evenly matched — NEPH and GWW each lead in 1 of 2 comparable metrics.
Risk & Volatility
NEPH is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than CNMD's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GWW currently trades 95.9% from its 52-week high vs NEPH's 54.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.58x | 0.89x | 0.87x | 1.32x |
| 52-Week HighHighest price in past year | $6.42 | $111.53 | $1286.56 | $61.08 |
| 52-Week LowLowest price in past year | $1.88 | $83.42 | $906.52 | $33.21 |
| % of 52W HighCurrent price vs 52-week peak | +54.8% | +89.1% | +95.9% | +60.2% |
| RSI (14)Momentum oscillator 0–100 | 54.6 | 51.4 | 69.6 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 35K | 275K | 237K | 403K |
Analyst Outlook
Evenly matched — GWW and CNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: FELE as "Hold", GWW as "Hold", CNMD as "Hold". Consensus price targets imply 112.2% upside for CNMD (target: $78) vs -3.3% for GWW (target: $1193). For income investors, CNMD offers the higher dividend yield at 2.16% vs GWW's 0.79%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $100.00 | $1193.14 | $78.00 |
| # AnalystsCovering analysts | — | 11 | 38 | 21 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% | +0.8% | +2.2% |
| Dividend StreakConsecutive years of raises | 0 | 32 | 37 | 2 |
| Dividend / ShareAnnual DPS | — | $1.11 | $9.73 | $0.79 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.8% | +1.8% | 0.0% |
GWW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CNMD leads in 1 (Valuation Metrics). 3 tied.
NEPH vs FELE vs GWW vs CNMD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NEPH or FELE or GWW or CNMD a better buy right now?
For growth investors, Nephros, Inc.
(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus 4. 5% for W. W. Grainger, Inc. (GWW). CONMED Corporation (CNMD) offers the better valuation at 24. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Franklin Electric Co. , Inc. (FELE) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NEPH or FELE or GWW or CNMD?
On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 24.
3x versus W. W. Grainger, Inc. at 34. 9x. On forward P/E, CONMED Corporation is actually cheaper at 8. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NEPH or FELE or GWW or CNMD?
Over the past 5 years, W.
W. Grainger, Inc. (GWW) delivered a total return of +167. 8%, compared to -71. 8% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: GWW returned +462. 8% versus CNMD's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NEPH or FELE or GWW or CNMD?
By beta (market sensitivity over 5 years), Nephros, Inc.
(NEPH) is the lower-risk stock at 0. 58β versus CONMED Corporation's 1. 32β — meaning CNMD is approximately 128% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 81% for CONMED Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NEPH or FELE or GWW or CNMD?
By revenue growth (latest reported year), Nephros, Inc.
(NEPH) is pulling ahead at 32. 7% versus 4. 5% for W. W. Grainger, Inc. (GWW). On earnings-per-share growth, the picture is similar: W. W. Grainger, Inc. grew EPS -8. 6% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NEPH or FELE or GWW or CNMD?
W.
W. Grainger, Inc. (GWW) is the more profitable company, earning 9. 5% net margin versus 3. 4% for CONMED Corporation — meaning it keeps 9. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GWW leads at 15. 0% versus 6. 1% for NEPH. At the gross margin level — before operating expenses — NEPH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NEPH or FELE or GWW or CNMD more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 4x forward P/E versus 27. 7x for W. W. Grainger, Inc. — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 112. 2% to $78. 00.
08Which pays a better dividend — NEPH or FELE or GWW or CNMD?
In this comparison, CNMD (2.
2% yield), FELE (1. 1% yield), GWW (0. 8% yield) pay a dividend. NEPH does not pay a meaningful dividend and should not be held primarily for income.
09Is NEPH or FELE or GWW or CNMD better for a retirement portfolio?
For long-horizon retirement investors, W.
W. Grainger, Inc. (GWW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 0. 8% yield, +462. 8% 10Y return). Both have compounded well over 10 years (GWW: +462. 8%, CNMD: +3. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NEPH and FELE and GWW and CNMD?
These companies operate in different sectors (NEPH (Healthcare) and FELE (Industrials) and GWW (Industrials) and CNMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NEPH is a small-cap high-growth stock; FELE is a small-cap quality compounder stock; GWW is a mid-cap quality compounder stock; CNMD is a small-cap quality compounder stock. FELE, GWW, CNMD pay a dividend while NEPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.